Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Penelope MacRae

Set Alert for Articles By Penelope MacRae

Latest From Penelope MacRae

Strides Injectables Re-Entry Shifts Into High Gear

Strides Pharma Science, which has reported a strong second-quarter performance, said its reborn injectables business will “be full-blown” in several markets by December thanks to the expiry of a non-compete agreement with Mylan.

Strategy Sales & Earnings

Biocon Biologics Eyes Sales Of $1bn

Strong growth in Biocon's biologics segment continued in the second quarter and the vertical has now set a target of $1bn in annual sales by the 2021-22 fiscal year.

Sales & Earnings Strategy

Biocon Biologics Eyes $1bn In Sales As Q2 Revenues Jump 40%

Strong growth in Biocon's biologics segment continued in the second quarter and the vertical has now set a target of $1bn in annual sales by the 2021-22 fiscal year.

India Biologics

WHO Must Overhaul Biosimilar Approval Guidelines

Civil society groups from around the world are pushing the World Health Organization to update its guidelines for approving biosimilars in order to make them affordable and accessible for patients, especially those in poorer countries.

Biosimilars Regulation

FDA Warning Letter Blasts Glenmark

Glenmark, which has been the recipient of a string of notices from the US Food and Drug Administration over manufacturing quality issues, is again under fire with the regulator blasting the leading Indian drugmaker for failing to ensure “consistent production” of safe and effective products.

Manufacturing Compliance

Centrient Slaps Dalas With Second Amoxicillin Lawsuit

Netherlands-based Centrient Pharmaceuticals, a global leader in producing “sustainable” enzymatic antibiotics, next-generation statins and antifungals, has filed a second lawsuit against Indian company Dalas Biotech accusing it of patent infringement.

Intellectual Property India
See All
UsernamePublicRestriction

Register